SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Reuters
05-23
May 23 (Reuters) - SpringWorks Therapeutics Inc :: *SPRINGWORKS THERAPEUTICS RECEIVES POSITIVE CHMP OPINION FOR MIRDAMETINIB FOR TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH NF1-PN *SPRINGWORKS THERAPEUTICS INC: DECISION FROM EUROPEAN COMMISSION EXPECTED IN Q3 2025